Results 61 to 70 of about 14,556 (187)

VII CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION»

Фармакоэкономика, 2015
VII CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION»

doaj   +2 more sources

Navigating Healthcare Economics Optimizing Therapeutic Efficacy and Cost with Pharmacoeconomics

Journal of Pharmacoeconomics and Pharmaceutical Management
Background:  In today's healthcare landscape, escalating costs underscore the pressing need for pharmacoeconomic evaluations, particularly in low- and middle-income countries (LMICs) where medication expenses can dominate healthcare budgets ...
Rania Indu, Moumita Ray, Sudipto Mangal
doaj  

Pharmacoeconomics of Bronchial Asthma

Folia Medica, 2019
Introduction: Pharmacoeconomics (PE) treats the problems of pharmacotherapy policy, drug marketing and reimbursement and clinical trials. It guides policy makers for effective health resources utilization and determines the profitability of the new drugs
Ivanova Zlatina I., Ivanov Yavor Y.
doaj   +1 more source

National and Individual‐Level Economic Burden of Local Corticosteroid Use and Concomitant Use of Multiple Local Corticosteroid Formulations—A Nationwide Cohort Study

Clinical &Experimental Allergy, EarlyView.
Kjell Erik Julius Håkansson, Jonas Bækdal, Inge Raadal Skov, Steven Arild Wuyts Andersen, Zarqa Ali, Anders Løkke, Rikke Ibsen, Ole Hilberg, Howraman Meteran, Claus Rikard Johnsen, Vibeke Backer, Charlotte Suppli Ulrik   +11 more
wiley   +1 more source

Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2607-2623, August 2026.
Abstract The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug‐resistant tuberculosis (TB) containing a bedaquiline–pretomanid‐based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by ...
Nisa Maria, Annisa Lazuardi Larasati, Indri Yuliani Hamdani, Jin‐Gun Cho, Jan‐Willem C. Alffenaar   +4 more
wiley   +1 more source

Impact of Bone Marrow Involvement on the Success of Hematopoietic Stem Cell Mobilization in Patients With Lymphoma

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT The influence of bone marrow (BM) involvement at diagnosis on hematopoietic stem cell (HSC) mobilization outcomes remains to be fully elucidated, particularly in the contemporary plerixafor era. To address this issue, this multicenter retrospective cohort study including four lymphoma treatment centers evaluated patients who underwent their ...
Jie Lv, Zailin Yang, Xiaoqian Liu, Yao Liu, Weiping Liu, Jun Zhu, Ling Wang, Yuqin Song, Chen Zhang   +8 more
wiley   +1 more source

Pharmacoeconomics of HIV-infection

Регуляторные исследования и экспертиза лекарственных средств, 2018
Ever since the first registrations of HIV-infections at the territory of the Russian Federation there was started a great process on arrangement and, subsequently, development of anti-HIV system.
R. I. Yagudina, A. U. Kulikov, V. V. Babiy, E. E. Arinina   +3 more
doaj  

Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 440-451, August 2026.
The Coalition to Advance Real‐World Evidence through Randomized Controlled Trial Emulation (CARE) Initiative seeks to advance understanding of when real‐world data (RWD) can generate valid treatment effectiveness estimates by emulating completed oncology randomized controlled trials (RCTs).
Natalie Levy, Paige Sheridan, Ulka Campbell, David Lenis, Inish O'Doherty, Adina Estrin, Nileesa Gautam, Monica Iyer, Sarah McDonald, Andrew Belli, Gillis Carrigan, K. Arnold Chan, James Chen, Victoria Chia, Neil Dhopeshwarkar, Joy Eckert, Laura Fernandes, Joel Greshock, Rachele Hendricks‐Sturrup, Jenny Huang, XiaoLong Jiao, Sajan Khosla, Orsolya Lunacsek, Lynn McRoy, Yanina Natanzon, Osayi Ovbiosa, Nelson Pace, Simone Pinheiro, Megan Rees, Jennifer Rider, Mothaffar Fahed Rimawi, Travis Robinson, Carla Rodriguez‐Watson, Chithra Sangli, Khaled Sarsour, Sebastian Schneeweiss, Mark Shapiro, Mark Stewart, Aliki Taylor, C. K. Wang, Shirley Wang, Yiduo Zhang, Ann Madsen   +42 more
wiley   +1 more source

Development and validation of the Chinese patient-centered integrated care scale

BMC Health Services Research
Background The healthcare system is currently facing challenges in transitioning to a more integrated, patient-centered care. China has implemented various practical exploration and pilot programs in developing an integrated healthcare service system ...
Yue Yin, Wenqing Gao, Xiujuan Cui, Wenxi Tang   +3 more
doaj   +1 more source

PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE

Кардиоваскулярная терапия и профилактика, 2015
Eplerenone (Inspra, Pfizer) improves the prognosis of patients with chronic heart failure and heart failure after acute myocardial infarction. Since Russia eplerenone pharmacoeconomics issues rarely discussed, the analysis of the literature on this topic
Yu. M. Lopatin, E. Yu. Lopatina
doaj   +1 more source